{"id":"oxetorone","rwe":[],"tags":[{"label":"oxetorone","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"N02CX06","category":"atc"},{"label":"Active","category":"status"},{"label":"Migraine","category":"indication"}],"phase":"phase_2","safety":{"safetySignals":[{"llr":62.978,"date":"","count":10,"signal":"Polycythaemia","source":"DrugCentral FAERS","actionTaken":"Reported 10 times (LLR=63)"}],"commonSideEffects":[{"effect":"Polycythaemia","drugRate":"LLR 63","severity":"common"}]},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["oxetorone fumarate","oxetorone"],"offLabel":[],"synonyms":["oxetorone fumarate","oxetorone"],"timeline":[],"approvals":[],"ecosystem":[{"indication":"Migraine","otherDrugs":[{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"almotriptan","slug":"almotriptan","company":"Janssen Pharms"},{"name":"caffeine","slug":"caffeine","company":"Novartis"},{"name":"dihydroergotamine","slug":"dihydroergotamine","company":"Valeant"}],"globalPrevalence":1000000000}],"mechanism":{"modality":"Small Molecule","drugClass":"oxetorone","explanation":"Imagine your brain has a messaging system that helps you feel pain. Oxetorone is believed to help regulate this system by influencing the chemicals that carry pain messages. This can help reduce the severity of migraine headaches.","oneSentence":"Oxetorone is thought to work by modulating the activity of certain neurotransmitters involved in pain transmission.","technicalDetail":"Oxetorone is a small molecule that acts as a modulator of neurotransmitter activity, potentially influencing the activity of GABA and glutamate receptors in the brain."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2019","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=OXETORONE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=OXETORONE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:13:03.561759","biosimilars":[],"competitors":[{"drugName":"clonidine","drugSlug":"clonidine","fdaApproval":"1974-09-03","patentExpiry":"Sep 8, 2031","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"oxetorone","indications":{"approved":[{"name":"Migraine","source":"DrugCentral","snomedId":37796009,"regulator":"FDA","usPrevalence":39000000,"globalPrevalence":1000000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Neurology, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"clonidine","brandName":"clonidine","genericName":"clonidine","approvalYear":"1974","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00904527","phase":"NA","title":"Interest of Relaxation From Patients With Pain Due to Migraine","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2006-06","conditions":["Migraine"],"enrollment":60,"completionDate":"2009-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"005618","UNII":"T3XOS33TIQ","CHEBI":"CHEBI:135364","INN_ID":"2840","RXNORM":"32633","UMLSCUI":"C0069760","ChEMBL_ID":"CHEMBL3989752","KEGG_DRUG":"D05290","DRUGBANK_ID":"DB13463","PUBCHEM_CID":"36846","SECONDARY_CAS_RN":"34522-46-8","MESH_SUPPLEMENTAL_RECORD_UI":"C011962"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":20,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N02CX06","allCodes":["N02CX06"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"OXETORONE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxetorone is a small molecule drug in the oxetorone class, originally developed by an unknown entity and currently owned by an unknown entity. It is used to treat migraine, but its exact target is unknown. The commercial status of oxetorone is unclear, as it is unknown whether it is patented or available as a generic medication. Key safety considerations for oxetorone are not well-documented. Further research is needed to fully understand the pharmacology and safety profile of this medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}